Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
AssigneeRinat Neuroscience Corp.
InventorsArnon Rosenthal, David Louis Shelton, Patricia Ann Walicke
Life of this patent
Estimating the term…
Abstract
The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
Claims38
A method for reducing stiffness in an individual having osteoarthritis comprising administering an effective amount of a monoclonal anti-NGF antagonist antibody to the individual, wherein the anti-NGF antagonist antibody blocks the interaction of human NGF with p75 and trkA,
- wherein the anti-NGF antagonist antibody:
- (a) binds NGF with a KD of less than about 2 nM;
- (b) inhibits human NGF-dependent survival of mouse E13.5 trigeminal neurons with an IC50 of about 100 pM or less, wherein the IC50 is measured in the presence of about 15 pM human NGF;
- and (c) inhibits human NGF-dependent survival of mouse E 13.5 trigeminal neurons with an IC50 of about 10 pM or less, wherein the IC50 is measured in the presence of about 1.5 pM of NGF.
A method for reducing stiffness in an individual having osteoarthritis comprising administering an effective amount of a monoclonal anti-NGF antagonist antibody to the individual, wherein the anti-NGF antagonist antibody blocks the interaction of human NGF with p75 and trkA,
- wherein the anti-NGF antagonist antibody binds to an epitope comprising:
- residues K32, K34 and E35 within variable region 1 of human NGF (hNGF);
- residues F79 and T81 within variable region 4 of hNGF;
- residues H84 and K88 within variable region 4 of hNGF;
- and/or residue R103 between variable region 5 of hNGF and the C-terminus.
Dependencies are inferred from the claim text.